MedTrace Logo

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04921358 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2025-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who experienced disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody treatment, with the anti-PD-(L)1 antibody administered either in combination with or sequentially before or after the platinum-based chemotherapy.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Tislelizumab

200 mg intravenously once every 3 weeks

DRUG

Docetaxel

75 mg/m\^2 intravenously once every 3 weeks

DRUG

Sitravatinib

100 mg orally once daily

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2023-12-20
Completion
2023-12-20

Countries

  • Australia
  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921358 on ClinicalTrials.gov